



(51) International Patent Classification:

A61K 38/16 (2006.01) C07K 14/21 (2006.01)  
A61K 9/00 (2006.01) A61P 31/04 (2006.01)

(21) International Application Number:

PCT/EP2015/071768

(22) International Filing Date:

22 September 2015 (22.09.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1416788.6 23 September 2014 (23.09.2014) GB

(71) Applicant: **THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW** [GB/GB]; Gilbert Scott Building, University Avenue, Glasgow Strathclyde G12 8QQ (GB).

(72) Inventors: **WALKER, Daniel**; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Strathclyde G12 8AT (GB). **MCCAUGHEY, Laura**; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Strathclyde G12 8AT (GB).

(74) Agents: **FORREST, Graham** et al.; Mewburn Ellis LLP, City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— of inventorship (Rule 4.17(iv))

**Published:**

— with international search report (Art. 21(3))

(54) Title: PULMONARY ADMINISTRATION OF PYOCINS FOR TREATING BACTERIAL RESPIRATORY INFECTIONS

(57) Abstract: The invention relates to the treatment of bacterial respiratory infections using the bacterially-originating antibiotics known as pyocins. In particular, the invention provides the use of S-type pyocins, administered by pulmonary administration, for the treatment of such infections.



WO 2016/046218 A1

PULMONARY ADMINISTRATION OF PYOCINS FOR TREATING BACTERIAL RESPIRATORY  
INFECTIONS**Field of the invention**

5 The invention relates to the treatment of bacterial  
respiratory infections, and in particular to the use of the  
bacterially-originating antibiotics known as pyocins to treat  
such infections.

**Background to the invention**

10 For Gram-negative pathogens such as *Pseudomonas aeruginosa*,  
*Klebsiella pneumoniae* and *Escherichia coli* therapeutic options  
are often limited. This is due to the horizontal acquisition  
of antibiotic resistance determinants and the presence of a  
highly impermeable outer-membrane that severely limits the  
15 efficacy of many classes of antibiotics<sup>1-3</sup>. In the case of the  
opportunistic pathogen *P. aeruginosa*, clinical isolates with  
resistance to all available antibiotics are prevalent  
worldwide and between 18 and 25% of clinical isolates are  
multidrug resistant<sup>1,4</sup>. In addition, the ability of *P.*  
20 *aeruginosa* to form multidrug resistant biofilms during chronic  
infection and the appearance of antibiotic resistant  
phenotypic variants during prolonged antibiotic therapy can  
render this pathogen essentially untreatable with existing  
antibiotics<sup>5-7</sup>. Chronic infection of the lower respiratory tract  
25 with *P. aeruginosa* is the leading cause of mortality in  
patients with cystic fibrosis, who despite receiving intensive  
antibiotic therapy have a median predicted survival of 41.5  
years (2011)<sup>8</sup>. In addition, infection with *P. aeruginosa* is a  
major and growing cause of nosocomial infections such as  
30 ventilator-associated pneumonia. *P. aeruginosa* infection is  
also linked with the pathogenesis of chronic obstructive  
pulmonary disease, a leading cause of death in the Western  
world<sup>9-12</sup>. Consequently, there is an urgent need to consider  
alternative strategies for antibiotic development, to bolster  
35 a developmental pipeline that in recent decades has yielded  
few novel small molecule antibiotics active against these  
difficult to treat bacteria<sup>13-15</sup>.

An alternative strategy for the discovery of effective antibiotics is to exploit the potent narrow-spectrum antibiotics produced by many bacteria for intraspecies competition. In *P. aeruginosa*, *K. pneumoniae* and *E. coli* these take the form of multi-domain protein antibiotics known as the S-type pyocins, klebicins and colicins respectively<sup>16-18</sup>. These bacteriocins have evolved to efficiently cross the Gram-negative outer membrane through the parasitisation of existing active nutrient uptake pathways, which are an Achilles' heel for Gram-negative bacteria<sup>19-24</sup>. The cellular targets of these protein antibiotics are highly conserved, with cytotoxic activity most commonly taking the form of a nuclease activity targeting DNA, rRNA or tRNA, or a pore-forming activity targeting the cytoplasmic membrane<sup>17</sup>. For the pyocins that have been characterized to date it is known that pyocins S1, S2, S3 and AP41 display DNase activity, pyocin S4 is a tRNase and pyocin S5 is a pore-forming toxin<sup>16</sup>. For the recently described lectin-like pyocin L1 the mechanism of cell killing is unknown.

#### **Summary of the invention**

Although pyocins display unmatched potency against *P. aeruginosa*, and pyocin S2 is active in an invertebrate model of *P. aeruginosa* infection<sup>25</sup>, pyocins have not previously been suggested or shown to be good candidates for clinical use. As bacterially-derived polypeptides, they would appear particularly unsuitable for use in treating conditions affecting the respiratory tract, since the presence of bacterial proteins in the lung would be expected to provoke an immune response which could be very damaging to the sensitive respiratory tissue.

Surprisingly, the present inventors have found that S-type pyocins can be successfully delivered to the lung, providing a dramatic reduction in bacterial load, but without provoking an immune response or causing other tissue damage.

The invention provides an S-type pyocin for use in a method of prophylaxis or treatment of a bacterial respiratory infection, wherein the pyocin is delivered by pulmonary administration.

5 The invention further provides the use of an S-type pyocin in the manufacture of a medicament for the prophylaxis or treatment of a bacterial respiratory infection, wherein the pyocin is delivered by pulmonary administration.

10 The invention further provides a method for prophylaxis or treatment of bacterial respiratory infection in a subject wherein an S-type pyocin is delivered to the subject by pulmonary administration.

15 The infecting bacteria typically comprise *Pseudomonas* species, such as *Pseudomonas aeruginosa*.

The subject to be treated may have, or may be at risk of developing a bacterial pneumonia as a result of the infection.

20 Thus the S-type pyocins may be used for the prophylaxis and/or treatment of bacterial pneumonia.

The subject to be treated may have compromised respiratory tract function and/or compromised immune function.

25 The subject to be treated may be suffering from cystic fibrosis or chronic obstructive pulmonary disease (COPD). Alternatively, the subject may be a cancer patient (especially one undergoing chemotherapy), or a patient affected by  
30 congestive heart failure or AIDS.

The subject to be treated may have, or be at risk of developing, community-acquired pneumonia and nosocomial infections such as ventilator-associated pneumonia and  
35 hospital-acquired pneumonia.

As described in more detail below, S-type pyocins comprise a targeting portion and an effector portion.

5 The S-type pyocin may, for example, comprise an S2, SD2, S5 or AP41 targeting portion. In some embodiments, the pyocin comprises an S5 targeting portion.

10 Additionally or alternatively, the S-type pyocin may, for example, comprise an S2, SD2, S5 or AP41 effector portion. Alternatively it may comprise a cytotoxic domain from a colicin, e.g. from an E2 or E3 colicin. In some embodiments, the pyocin comprises an S5 effector portion.

15 In some embodiments, the S-type pyocin is an SD2, SD2, S5, AP41 or L1 pyocin, e.g. an S5 pyocin.

20 It may be desirable that a combination of two or more pyocins is administered to the subject. The combination may comprise S-type pyocins having at least two different receptor specificities and/or effector activities.

The combination may comprise an S5 pyocin.

25 The combination may comprise an L1 pyocin.

The combination may comprise an S2 pyocin.

The combination may comprise an AP41 pyocin.

30 The combination may comprise an SD2 pyocin.

35 The combination may comprise an L1 pyocin and an S2 pyocin; an L1 pyocin and an AP41 pyocin; an S2 pyocin and an AP41 pyocin; or an L1 pyocin, an S2 pyocin and an AP41 pyocin. Any of these combinations may additionally comprise an S5 pyocin and/or an SD2 pyocin. Whichever other pyocins are present, it may be desirable that the combination comprises an S5 pyocin.

The invention further provides a method of preparing a medicament for the prophylaxis or treatment of bacterial respiratory infection comprising providing an S-type pyocin and formulating said S-type pyocin for pulmonary administration.

The S-type pyocin may have been expressed by recombinant methods.

10

The method may comprise the steps of recombinantly expressing the S-type pyocin and optionally isolating the S-type pyocin.

15

The invention further provides a device for pulmonary administration of an active agent to a subject, the device comprising an S-type pyocin. The device may, for example, be an inhaler (e.g. metered-dose inhaler, dry powder inhaler) or nebuliser (e.g. ultrasonic nebuliser, jet nebuliser, vibrating mesh nebuliser).

20

The invention will now be described in more detail, by way of example and not limitation, by reference to the accompanying drawings and examples.

25

#### **Description of the Drawings**

**Figure 1.** *P. aeruginosa* P8 bacterial recovery from pyocin treated mice. All pyocins were given at 3 mg ml<sup>-1</sup>. Bacterial counts determined by CFU counts of homogenized lungs. (a) Mice treated with pyocin 6 h pre-infection, all mice culled 5 h post-infection (b) Mice treated with pyocin 6 h pre-infection, pyocin treated mice survived to 24 h (c) Mice treated with pyocin 1 h post-infection, all mice culled 4.5 h post-infection (d) Mice treated with pyocin 1 h post-infection, pyocin treated mice survived to 24 h. No colonies were recovered from pyocin S5 treated mice in a) b) and d). Bars represent Mean ± SEM, \* denotes statistical significance for

35

comparison of treatment versus control by a one-sided Mann-Whitney U test with Bonferroni correction applied.

**Figure 2.** Pyocin S5 and tobramycin treatment of *P. aeruginosa* P8 infected mice. (A) Mice treated 1 h post-infection, all mice culled 4.5 h post-infection (B) Mice treated 1 h post-infection, S5 30 ng ml<sup>-1</sup> and tobramycin 300 µg ml<sup>-1</sup> mice survived to 24 h. All other mice culled 5.5 h post-infection. Bars represent Mean ± SEM, \* denotes statistical significance for comparison of treatment versus control by a one-sided Mann-Whitney U test with Bonferroni correction applied.

**Figure 3.** Acquired tolerance to pyocins can be overcome by treating with a range of pyocins. (a) Spot tests to determine cytotoxic activity of pyocins S5, AP41 and L1. Purified protein at 200 µg ml<sup>-1</sup> was spotted onto a growing lawn of bacteria. Clear zones indicate pyocin cytotoxicity. P8AP41T is an AP41 tolerant strain of P8 and P8AP41T\* is strain P8AP41T recovered from untreated control mice shown in (b). (b) Bacterial counts for mice infected with P8AP41T shown in (a), then treated 1 h post-infection with pyocins at 3 mg ml<sup>-1</sup>. Pyocin treated mice survived to 24 h. No colonies were recovered from pyocin S5 treated mice. Bars represent Mean ± SEM, \* denotes statistical significance for comparison of treatment versus control by a one-sided Mann-Whitney U test with Bonferroni correction applied.

**Figure 4.** Pyocin combinations for the treatment of *P. aeruginosa* P8 infected mice. Mice treated 1 h post-infection with pyocins at stock concentrations of 300 µg ml<sup>-1</sup>; pyocin treated mice survived to 24 h. Bars represent Mean ± SEM, \* denotes statistical significance for comparison of treatment versus control by a one-sided Mann-Whitney U test with Bonferroni correction applied.

**Figure 5.** Biological repeats of experiments in Figures 1 (c) and (d). *P. aeruginosa* P8 bacterial recovery from pyocin

treated mice. All pyocins were given at 3 mg ml<sup>-1</sup>. Bacterial counts determined by CFU counts of homogenized lungs. Counts from pyocin treated mice were compared to those from PBS treated mice (a) Mice treated with pyocin 1 h post-infection, all mice culled 4.5 h post-infection (b) Mice treated with pyocin 1 h post-infection, pyocin treated mice survived to 24 h. Bars represent Mean ± SEM, \* denotes statistical significance for comparison of treatment versus control by a one-sided Mann-Whitney U test with Bonferroni correction applied.

**Figure 6.** Repeat of experiment in Figure 2 (a). Pyocin S5 and tobramycin treatment of *P. aeruginosa* P8 infected mice. Mice treated 1 h post-infection, all mice culled 4.5 h post-infection. Bars represent Mean ± SEM, \* denotes statistical significance for comparison of treatment versus control by a one-sided Mann-Whitney U test with Bonferroni correction applied.

**Figure 7.** Pyocin SD2 for the treatment of *P. aeruginosa* PA01 infected mice. Mice treated 1 h post-infection with pyocin SD2 at a stock concentration of 3 mg ml<sup>-1</sup>. Control mice were culled at 6 h post-infection and pyocin SD2 treated mice survived to 24 h. Bars represent Mean ± SEM, \* denotes statistical significance for comparison of treatment versus control by a one-sided Mann-Whitney U test with Bonferroni correction applied.

**Figure 8.** Pyocin S5 can afford protection against lethal *P. aeruginosa* infections in the presence of pyocin S5 antibodies. (a) Bacterial counts for mice repeatedly exposed to pyocin S5 or PBS intranasally and subsequently infected with *P. aeruginosa* P8 and treated with pyocin S5 or PBS post infection. Bacterial counts determined by CFU counts from homogenised lungs. Multiple doses of pyocin S5 (75 µg/dose) were administered three times, two weeks apart over four

weeks. At thirteen weeks, mice were infected with *P. aeruginosa* P8 and treated with pyocin S5 (75 µg) or PBS 1 h post-infection. \* Denotes statistical significance for comparison of treatment versus control by a one-sided Mann-Whitney U test with Bonferroni correction applied. (b) IgG and IgA serum levels for mice repeatedly exposed to pyocin S5 or PBS (as described in a). The control group were administered pyocin S5 (75 µg/dose) with Freund's complete/incomplete subcutaneously three times, two weeks apart. Bars represent Mean ± SEM. (c) and (d) as for (a) and (b) except mice were repeatedly exposed to pyocin S5 via the intraperitoneal (I.P.) route.

### Detailed Description of the Invention

#### **Pyocins**

Pyocins are proteinaceous anti-microbial toxins produced by and effective against *Pseudomonas* species, especially *P. aeruginosa*.

Pyocins generally fall into three classes, namely S-type, R-type and F-type.

R-type (rod-like) and F-type (flexible and non-contractile) pyocins are both related to phage tail proteins (from P2 phage and lambda phage respectively) and act by forming pores in the bacterial membrane.

S-type (soluble) pyocins have characteristic multi-domain structures similar to colicins (to which they are believed to be evolutionarily related). The term "pyocin" is used in this specification to refer to S-type pyocins except where the context demands otherwise. Organisms which produce S-type pyocins are normally unaffected by their own pyocins because they also produce "immunity proteins" which act as antagonists to the corresponding pyocins.

S-type pyocins comprise a targeting portion and an effector portion. Typically the targeting portion is at the N-terminal end of the molecule and the effector portion at the C-terminal end. However, the order of these portions may not be essential for function. Thus use of pyocin molecules having an N-terminal effector portion and a C-terminal targeting portion is also contemplated.

The effector portion may constitute a single independently folded domain. The targeting portion may also constitute a single independently folded domain or may be sub-divided into two or more independently folded domains.

The targeting portion binds to a receptor at the surface of the target organism (i.e. at the Gram negative outer membrane) and mediates translocation of the pyocin across the outer membrane. For the avoidance of doubt, the term "receptor" is used simply to designate the molecule on the target organism to which the targeting portion binds, and should not be taken to imply a cooperative receptor-ligand interaction in the sense usually intended for a pair of molecules expressed by a single organism.

In general, the targeting portion of the pyocin determines the species and strain specificity (or tropism) of the pyocin. The receptors to which they bind are often specific to pseudomonads, e.g. to *Pseudomonas*, or even to *P. aeruginosa* or strains thereof.

The targeting portions of most naturally occurring S-type pyocins have a characteristic modular structure containing up to three identifiable sub-regions, each of which may represent an separately folded domain or may lack recognisable secondary structure and thus form a flexible region of the molecule. These sub-regions are often referred to in the literature as a receptor binding region, a region of unknown function, and a translocation region, and typically (although not exclusively)

occur in that order in an N- to C-terminal direction.  
However, these proteins are not well characterised and the  
ascribed functions may not be correct. These regions will  
therefore be referred to herein as regions I, II and III of  
5 the targeting portion respectively.

Without wishing to be bound by any particular theory, it is  
believed that regions I, II and III may be interchangeable  
between pyocin molecules, at least to some extent, and that  
10 region II may be dispensable in whole or in part. Thus, the  
targeting portion may comprise at least a region I sequence  
and a region III sequence, optionally separated by a region II  
sequence, a fragment thereof, or a peptide linker. It may be  
desirable that region I, region II or fragment or linker (if  
15 present), and region III occur in that order in an N- to C-  
terminal direction.

The effector portion typically has cell-killing activity once  
across the outer membrane. It may act in the periplasm or may  
20 require transport to the cytoplasm to exert its cell-killing  
effect. Regardless of mechanism, the effector portion may be  
referred to as a "cytotoxic" portion of the pyocin molecule.

The effector or cytotoxic portions of pyocin molecules are  
25 typically pore-forming or enzymatic. Pore-forming pyocins,  
e.g. pyocin S5, kill target cells by depolarisation of the  
cytoplasmic membrane. Enzymatic pyocins typically act as  
nucleases in the cytoplasm and include those with DNase  
activity (e.g. pyocins S1, S2, SD2, S3 and AP41) and tRNase  
30 activity (e.g. pyocin S4).

The targets on which the effector portions act tend to be  
highly conserved across the bacterial kingdom and their  
mechanisms of action are similar to those of other anti-  
35 bacterial toxins such as the effector domains of colicins.  
Indeed, chimeric pyocins containing a targeting portion from  
an S1 or S2 pyocin linked to an effector portion from either

an E2 or E3 colicin have been demonstrated to retain  
pseudomonad-killing activity<sup>37</sup>. Thus the pyocin may comprise  
any suitable anti-bacterial protein or protein domain as an  
effector portion, as long as the protein or domain retains  
5 cytotoxic activity against one or more pseudomonad organisms.  
For example, the effector component may be a cytotoxic domain  
from a colicin, such as (but not limited to) an E2 or E3  
colicin.

10

Pyocin S2

The targeting domains of S2 pyocins bind to the TonB-dependent iron-siderophore receptor FpvAI. S2 effector domains have DNase activity.

5

An example of an S2 pyocin has the sequence:

MAVNDYEPGSMVITHVQGGGRDIIQYIPARSSYGTPPFVPPGSPYVGTGMQEYRKLRLSTLD  
 KSHSELKKNLKNETLKEVDELKSEAGLPGKAVSANDIRDEKSIVDALMDAKAKSLKAIEDRP  
 ANLYTASDFPQKSESMYQSOLLASRKFYGEFLDRHMSELAKAYSADIYKAQIAILKQTSQEL  
 10 ENKARSLEAEAQRAAAEVEADYKARKANVEKKVQSELDQAGNALPQLTNPTPEQWLERATQL  
 VTQAIANKKKLQTANNALIAKAPNALEKQKATYNADLLVDEIASLQARLDKLNAE TARRKEI  
 ARQAAIRAANTYAMPANGSVVATAAGRGLIQVAQGAASLAQAISDAIAVLGRVLASAPSVMA  
 VGFASLTYSSRTAEQWQDQTPDSVRYALGMDAAKLGLPPSVNLNAVAKASGTVDLPMRLTNE  
 ARGNTTTL SVVSTDGVSVPKAVPVRMAAYNATTGLYEVTVPSTTAEAPPLILTWT PASPPGN  
 15 QNPSSTTPVVPKVPVYEGATLTPVKATPETYPGVITLPEDLIIGFPADSGIKPIYVMFRDP  
 RDVPGAATGKGQPVSGNWLGAASQGEGAPIPSQIADKLRGKTFKNWRDFREQFWIAVANDPE  
 LSKQFNPGSLAVMRDGGAPYVRESEQAGGRIKIEIHHKVRIADGGGVYMNGLVAVTPKRHI  
 EIHKGGK [SEQ ID NO: 1]

20

The targeting portion of the S2 pyocin has the sequence:

MAVNDYEPGSMVITHVQGGGRDIIQYIPARSSYGTPPFVPPGSPYVGTGMQEYRKLRLSTLD  
 KSHSELKKNLKNETLKEVDELKSEAGLPGKAVSANDIRDEKSIVDALMDAKAKSLKAIEDRP  
 ANLYTASDFPQKSESMYQSOLLASRKFYGEFLDRHMSELAKAYSADIYKAQIAILKQTSQEL  
 ENKARSLEAEAQRAAAEVEADYKARKANVEKKVQSELDQAGNALPQLTNPTPEQWLERATQL  
 25 VTQAIANKKKLQTANNALIAKAPNALEKQKATYNADLLVDEIASLQARLDKLNAE TARRKEI  
 ARQAAIRAANTYAMPANGSVVATAAGRGLIQVAQGAASLAQAISDAIAVLGRVLASAPSVMA  
 VGFASLTYSSRTAEQWQDQTPDSVRYALGMDAAKLGLPPSVNLNAVAKASGTVDLPMRLTNE  
 ARGNTTTL SVVSTDGVSVPKAVPVRMAAYNATTGLYEVTVPSTTAEAPPLILTWT PASPPGN  
 QNPSSTTPVVPKVPVYEGATLTPVKATPETYPGVITLPEDLIIGFPADSGIKPIYVMFRDP  
 30 [SEQ ID NO: 2]

Region I of the S2 targeting portion has the sequence:

MAVNDYEPGSMVITHVQGGGRDIIQYIPARSSYGTPPFVPPGSPYVGTGMQEYRKLRLSTLD  
 KSHSELKKNLKNETLKEVDELKSEAGLPGKAVSANDIRDEKSIVDALMDAKAKSLKAIEDRP  
 35 ANLYTASDFPQKSESMYQSOLLASRKFYGEFLDRHMSELAKAYSADIYKAQIAILKQTSQEL  
 ENKARSLEAEAQRAAAEVEADYKARKANVE [SEQ ID NO: 3]

Region II of the S2 targeting portion has the sequence:  
 KKVQSELDQAGNALPQLTNPTPEQWLERATQLVTQAIANKKKLQTANNALIAKAPNALEKQK  
 ATYNADLLVDEIASLQARLDKLNAAETARRKEIAR [SEQ ID NO: 4]

5 Region III of the S2 targeting portion has the sequence:  
 AAIRAANTYAMPANGSVVATAAGRGLIQVAQGAASLAQAISDAIAVLGRVLASAPSVMAVGF  
 ASLTYSSRTAEQWQDQTPDSVRYALGMDAAKLGPPSVNLNAVAKASGTVDLPMRLTNEARG  
 NTTTLSVVSTDGVSVPKAVPVRMAAYNATTGLYEVTVPSTTAEAPPLILTWTWPASPPGNQNP  
 SSTTPVVPKVPVYEGATLTPVKATPETYPGVITLPEDLIIGFPADSGIKPIYVMFRDP  
 10 [SEQ ID NO: 5]

The effector portion of the S2 pyocin has the sequence:  
 RDVPGAATGKGQPVSGNWLGAASQGEGAPIPSQIADKLRGKTFKNWRDFREQFWIAVANDPE  
 LSKQFNPGSLAVMRDGGAPYVRESEQAGGRIKIEIHHKVRIADGGGVYNMGNLVAVTPKRHI  
 15 EIHKGGK [SEQ ID NO: 6]

Pyocin SD2

A prototypical SD2 pyocin sequence is described by McCaughey  
 et al. (in press). The targeting domains of SD2 pyocins bind  
 20 to lipopolysaccharide (LPS) from *P. aeruginosa* and more  
 specifically to the common polysaccharide antigen (CPA) within  
 LPS, which is predominantly a homo-polymer of D-rhamnose.  
 although specific binding may not be required for killing.  
 SD2 effector domains are believed to have tRNase activity.

25 An example of an SD2 pyocin has the sequence:  
 MAVNDYEPGSMVITHVQGGGRDIIQYIPARSSYGTPPFVPPGSPYVGTGMQEYRKLRLSTLD  
 KSHSELKKNLKNETLKEVDELKSEAGLPGKAVSANDIRDEKSIVDALMDAKAKSLKAIEDRP  
 ANLYTASDFPQKSESMYQSQLLASRKFYGEFLDRHMSELAKAYSADIYKAQIAILKQTSQEL  
 30 ENKARSLEAEAQRAAAEVEADYKARKANVEKKVQSELDQAGNALPQLTNPTPEQWLERATQL  
 VTQAIANKKKLQTANNALIAKAPNALEKQKATYNADLLVDEIASLQARLDKLNAAETARRKEI  
 ARQAAIRAANTYAMPANGSVVATAAGRGLIQVAQGAASLAQAISDAIAVLGRVLASAPSVMA  
 VGFASLTYSSRTAEQWQDQTPDSVRYALGMDANKLGLTSSVNL SAVAKAGGTVDLPMRLTNE  
 ARGNTTTLVVSTDGVSVPKAAVVRMAAYNATTGLYEVTVPSTTAEAPPLILTWTWPASPPGN  
 35 QNPSSTTPVIPKVPVYEGAALTPLKTGPESYPGMLLDLNDLIVIFPADSGVKPVYVMLSSP  
 LD SGIFTRRQLQKKFDSHKYDFGLGEKSANNGTLAEFRDKILEHLADPATVEKGTYHSEVNS  
 KVHYNARTNIVVIIGEDGMFVSGWRIEPTDQYNFYMKNEVL [SEQ ID NO: 7]

The targeting portion of the SD2 pyocin has the sequence:

MAVNDYEPGSMVITHVQGGGRDIIQYIPARSSYGTPPFVPPGSPYVGTGMQEYRKLRLSTLD  
 KSHSELKKNLKNETLKEVDELKSEAGLPGKAVSANDIRDEKSIVDALMDAKAKSLKAIEDRP  
 ANLYTASDFPQKSESMYQSQLLASRKFYGEFLDRHMSELAKAYSADIYKAQIAILKQTSQEL  
 5 ENKARSLEAEAQRAAAEVEADYKARKANVEKKVQSELDQAGNALPQLTNPTPEQWLERATQL  
 VTQAIANKKKLQTANNALIAKAPNALEKQKATYNADLLVDEIASLQARLDKLNLAETARRKEI  
 ARQAAIRAANTYAMPANGSVVATAAGRGLIQVAQGAASLAQAISDAIAVLGRVLASAPSVMA  
 VGFASLTYSSRTAEQWQDQTPDSVRYALGMDANKLGLTSSVNL SAVAKAGGTVDLPMRLTNE  
 ARGNTTTL SVVSTDGVSVPKAA PVRMAAYNATTGLYEVTVPSTTAEAPPLILTWT PASPPGN  
 10 QNPSSTTPVIPKVPVYEGAALTPLKTGPESYPGMLLDLNDLIVIFPADSGVKPVYVM  
 [SEQ ID NO: 8]

Region I of the SD2 targeting portion has the sequence:

MAVNDYEPGSMVITHVQGGGRDIIQYIPARSSYGTPPFVPPGSPYVGTGMQEYRKLRLSTLD  
 15 KSHSELKKNLKNETLKEVDELKSEAGLPGKAVSANDIRDEKSIVDALMDAKAKSLKAIEDRP  
 ANLYTASDFPQKSESMYQSQLLASRKFYGEFLDRHMSELAKAYSADIYKAQIAILKQTSQEL  
 ENKARSLEAEAQRAAAEVEADYKARKANVE [SEQ ID NO: 9]

Region II of said pyocin SD2 targeting portion:

KKVQSELDQAGNALPQLTNPTPEQWLERATQLVTQAIANKKKLQTANNALIAKAPNALEKQK  
 20 ATYNADLLVDEIASLQARLDKLNLAETARRKEIAR [SEQ ID NO: 10]

Region III of the SD2 targeting portion has the sequence:

QAAIRAANTYAMPANGSVVATAAGRGLIQVAQGAASLAQAISDAIAVLGRVLASAPSVMAVG  
 25 FASLTYSSRTAEQWQDQTPDSVRYALGMDANKLGLTSSVNL SAVAKAGGTVDLPMRLTNEAR  
 GNTTTL SVVSTDGVSVPKAA PVRMAAYNATTGLYEVTVPSTTAEAPPLILTWT PASPPGNQN  
 PSSTTPVIPKVPVYEGAALTPLKTGPESYPGMLLDLNDLIVIFPADSGVKPVYVM [SEQ  
 ID NO: 11]

The effector portion of SD2 pyocin has the sequence:

LSSPLDSGIFTRRQLQKKFDSHKYDFGLGEKSANNGTLAEFRDKILEHLADPATVEKGTYHS  
 30 EVNSKVHYNARTNIVVIIGEDGMFVSGWRIE PGTDQYNFYMKNEVL [SEQ ID NO: 12]

Pyocin S5

35 The targeting domains of S5 pyocins bind to the TonB-dependent iron-siderophore receptor FptA. S5 effector domains have pore-forming activity.

Sequence analysis of the targeting portion of pyocin S5 suggests that region III may occur N-terminal of region I, and that region II may be absent.

5

An example of an S5 pyocin has the sequence:

MSNDNEVPGSMVIVAQGPDDQYAYEVPPIDSAAVAGNMFGDLIQREIYLQKNIYYPVRSIFE  
QGTKEKKEINKKVSDQVDGLLKQITQGKREATRQERVDVMSAVLHKMESDLEGYKKTFTKGP  
FIDYEKQSSLSIYEAWVKIWEKNSWEERKKYPFQQLVRDELERAVAYYKQDSLSEAVKVLRLQ  
10 ELNKQKALKEKEDLSQLERDYRTRKANLEMKVQSELDQAGSALPPLVSPTPEQWLERATRLV  
TQAIADKKQLQTTNNTLIKNSPTPLEKQKAIYNGELLVDEIASLQARLVKLN AETTRRRT  
ERKAAEQALQDAIKFTADFYKEVTEKFGARTSEMARQLAEGARGKNIRSSAEAIKSF  
DALNKKLSLKDRQAIAKAFDSLKQMMAKSLEKFSKGFVVGKAIDAASLYQEFKISTETGD  
WKPFVVKIETLAAGAAASWLVGIAFATATATPIGILGFALVMAVTGAMIDEDLLEKANLVI  
15 SI [SEQ ID NO: 13]

The targeting portion of the S5 pyocin has the sequence:

MSNDNEVPGSMVIVAQGPDDQYAYEVPPIDSAAVAGNMFGDLIQREIYLQKNIYYPVRSIFE  
QGTKEKKEINKKVSDQVDGLLKQITQGKREATRQERVDVMSAVLHKMESDLEGYKKTFTKGP  
20 FIDYEKQSSLSIYEAWVKIWEKNSWEERKKYPFQQLVRDELERAVAYYKQDSLSEAVKVLRLQ  
ELNKQKALKEKEDLSQLERDYRTRKANLEMKVQSELDQAGSALPPLVSPTPEQWLERATRLV  
TQAIADKKQLQTTNNTLIKNSPTPLEKQKAIYNGELLVDEIASLQARLVKLN [SEQ ID  
NO: 14]

Region I of the S5 targeting portion has the sequence:

ERKKYPFQQLVRDELERAVAYYKQDSLSEAVKVLRLQELNKQKALKEKEDLSQLERDYRTRKA  
NLEMKVQSELDQAGSALPPLVSPTPEQWLERATRLVTQAIADKKQLQTTNNTLIKNSPTPLE  
KQKAIYNGELLVDEIASLQARLVKLN [SEQ ID NO: 15]

Region III of the S5 targeting portion has the sequence:

MSNDNEVPGSMVIVAQGPDDQYAYEVPPIDSAAVAGNMFGDLIQREIYLQKNIYYPVRSIFE  
QGTKEKKEINKKVSDQVDGLLKQITQGKREATRQERVDVMSAVLHKMESDLEGYKKTFTKGP  
FIDYEKQSSLSIYEAWVKIWEKNSWE [SEQ ID NO: 16]

35

The effector portion of the S5 pyocin has the sequence:  
 AETTRRRTEAERKAAEEQALQDAIKFTADFYKEVTEKFGARTSEMARQLAEGARGKNIRSSA  
 EAIKSFEKHKDALNKKLSLKDRQAIKAFDSDLKQMMAKSLEKFSKGFVVGKAIDAASLYQ  
 EFKISTETGDWKPFVVKIETLAAGAAASWLVGIAFATATATPIGILGFALVMAVTGAMIDED  
 5 LLEKANNLVISI [SEQ ID NO: 17]

Pyocin AP41

The effector domains of AP41 pyocins have DNase activity.

10 An example of an AP41 pyocin has the sequence:  
 MSDVFDLGSMTTVATATGQYSFYTPPPPTPIPYLTYIARPGINKFDLPEGAKIKDLIKRYQY  
 IGSQIPAAIMIRGVQEEIKKSTNTALANVGAIVDGELAYLASQKKEKLNPAEATPLQMASAE  
 KAAVELLASKQKELADARTIANAFFGYDPLTVNYVNMNEIYGRREDKDFSFDNWSKSYSA  
 AQKIRLIEAKISVLNSRSSALDGKVAELTRLQRLQLEDAQHAAEAARQTEAERLAQEQRQAEAR  
 15 RQAEEARQAEARQAEELQRLAEAEAKRVAEAEKKRQDEINARLQAIVVSESEAKRIEEIYK  
 RLEEQDKISNPTVTTTPPAVDAGSRVDDALAHTGTRVTSGETGATGGSGRDVDTGTGQGGIT  
 ARPVDVGSVSI PDRRDPKIPDQPRRDLGSLVPTFPDFPTFPSFPGVGVPAAAKPLI PAGGGA  
 ASVSRTLKTAVDLLSVARKTPGAMLGQVAAVVATMAVSSFVPKLNNGERQASFAIPVAELSP  
 PLAVDWQAIAAAAGTVDLPYRLKTLNVDGSIQII IAVPTEPGSAAVPVRALTLDSASGTYKYT  
 20 TTGPGGGTILVTPDTPPGQIDPSSSTPAVPRGPLIMPGLLIPKEPQIESYPELDQREFNDG  
 IYVYPEDSGIPPLYIVYRDPRDEPGVATGNGQPVTGNWLAGASQGDGVPIPSQIADQLRGKE  
 FKS WRDFREQFWMAVSKDPSALENLSPSNRYFVSQGLAPYAVPEEHLGSKEKFEIHHVVPLE  
 SGGALYNIDNLVIVTPKRHSEIHKELKLRKEK [SEQ ID NO: 18]

25 The targeting portion of the AP41 pyocin has the sequence:  
 MSDVFDLGSMTTVATATGQYSFYTPPPPTPIPYLTYIARPGINKFDLPEGAKIKDLIKRYQY  
 IGSQIPAAIMIRGVQEEIKKSTNTALANVGAIVDGELAYLASQKKEKLNPAEATPLQMASAE  
 KAAVELLASKQKELADARTIANAFFGYDPLTVNYVNMNEIYGRREDKDFSFDNWSKSYSA  
 AQKIRLIEAKISVLNSRSSALDGKVAELTRLQRLQLEDAQHAAEAARQTEAERLAQEQRQAEAR  
 30 RQAEEARQAEARQAEELQRLAEAEAKRVAEAEKKRQDEINARLQAIVVSESEAKRIEEIYK  
 RLEEQDKISNPTVTTTPPAVDAGSRVDDALAHTGTRVTSGETGATGGSGRDVDTGTGQGGIT  
 ARPVDVGSVSI PDRRDPKIPDQPRRDLGSLVPTFPDFPTFPSFPGVGVPAAAKPLI PAGGGA  
 ASVSRTLKTAVDLLSVARKTPGAMLGQVAAVVATMAVSSFVPKLNNGERQASFAIPVAELSP  
 PLAVDWQAIAAAAGTVDLPYRLKTLNVDGSIQII IAVPTEPGSAAVPVRALTLDSASGTYKYT  
 35 TTGPGGGTILVTPDTPPGQIDPSSSTPAVPRGPLIMPGLLIPKEPQIESYPELDQREFNDG  
 IYVYPEDSGIPPLYIVYRD [SEQ ID NO: 19]

Region I of the AP41 targeting portion has the sequence:

MSDVFDLGSMTTVATATGQYSFYTPPPPTPIPYLTYIARPGINKFDLPEGAKIKDLIKRYQY  
 IGSQIPAAIMIRGVQEEIKKSTNTALANVGAIVDGELAYLASQKKEKLNPAEATPLQMASAE  
 KAAAVELLASKQKELADARTIANAFFGYDPLTVNYVNMNEIYGRREDKDFSFDNWSKSYSA  
 5 AQKIRLIEAKISVLNSRSSALDGKVAELTRLQRLEDAQHAAEAARQTEAERLA [SEQ ID  
 NO: 20]

Region II of the AP41 targeting portion has the sequence:

QEQRQAEARRQAEARRQAEARQQAELQRLAEAEAKRVAEAEKKRQDEINARLQAIIVSESE  
 10 AKRIEIIYKRLEEQDKISNPTVTTTPPAVDAGSRVDDALAHTGTRVTSGETGATGGSGRDVD  
 TGTGQGGITARPVDVGSVSIPDRRDPKIPDQPRRDL [SEQ ID NO: 21]

Region III of the AP41 targeting portion has the sequence:

GSLVPTFPDFPTFPSFPGVGVPAAAKPLIPAGGGAASVSRTLKTAVDLLSVARKTPGAMLGQ  
 15 VAAVVATMAVSSFWPKLNNGERQASFAIPVAELSPPLAVDWQAIAAAKGTVDLPYRLKTLNV  
 DGSIQIIAVPTEPGSAAVPVRALTLDSASGTYKYTTTGPGGGTILVTPDTPPGQIDPSSSTP  
 AVPRGPLIMPGTLLIPKEPQIESYPELDQREFNDGIYVYPEDSGIPPLYIVYRD [SEQ ID  
 NO: 22]

The effector portion of the AP41 pyocin has the sequence:

PRDEPGVATGNGQPVTGNWLAGASQGDGVPIPSQIADQLRGKEFKSWRDFREQFWMMAVSKDP  
 SALENLSPSNRYFVSQGLAPYAVPEEHLGSKEKFEIHHVVPLESGGALYNIDNLVIVTPKRH  
 SEIHKELKLRKEK [SEQ ID NO: 23]

### 25 Pyocin L1

Pyocin L1 can be regarded as a "lectin-like" pyocin, which binds to carbohydrate moieties on the bacterial surface. Its receptor on *P. aeruginosa* is believed to be LPS, and more specifically the common polysaccharide antigen (CPA) within  
 30 LPS, which is predominantly a homo-polymer of D-rhamnose.

For the purpose of this specification, it is regarded as an S-type pyocin because it is soluble and has no homology to phage tail proteins (and thus is not readily classifiable with R-type or F-type pyocins).  
 35

An example of an L1 pyocin has the sequence:

MASSLAPRQVIRDGQFITSPNGKYKLVMQADGNLVLYEDGTKPIWNTTPVGGP GAKAVMEFNL  
NLYNKAGQVAWSSNVYTAYLFEEFKDEAYLNLQDDGDFGIFSDEAKWGSIVLSRPEVGVKNK  
I IPTGTVMVPGTEYINGNYRLAFQGDGNLVIYQINPQVVIWATYTMGADRAVVQEDGNFVIY  
5 KGTTALWHTHTATGMPAYLKFTNTGKLFLSQPTLLWTLKRGSLSKPPKVI PGQHGPLDTP I  
WSWPHDYP [SEQ ID NO: 24]

The four underlined sequences are believed to represent  
carbohydrate-binding motifs. An L1 pyocin typically comprises  
10 one, two, three or four carbohydrate-binding motifs having the  
consensus sequence Q-X-D-X-N/D-X-V/G-Y/F.

Thus, the S-type pyocin for use in the present invention  
15 comprises a targeting portion which may comprise:

a region I sequence having at least 80% sequence identity,  
e.g. at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence  
identity, to the region I sequence from pyocin S2, SD2, S5 or  
20 AP41 (SEQ ID NOs: 3, 9, 15 and 20 respectively);

a region III sequence having at least 80% sequence identity,  
e.g. at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence  
identity, to the region III sequence from pyocin S2, SD2, S5  
25 or AP41 (SEQ ID NOs: 5, 11, 16 and 22 respectively);

and optionally:

a region II sequence having at least 80% sequence identity,  
30 e.g. at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence  
identity, to the region II sequence from pyocin S2, SD2 or  
AP41 (SEQ ID NOs: 4, 10 and 21 respectively).

The targeting portion may have at least 80% sequence identity,  
35 e.g. at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence  
identity to the targeting portion sequence from pyocin S2,  
SD2, S5 or AP41 (SEQ ID NOs: 2, 8, 14 and 19 respectively).

Such targeting portions may be described as S2, SD2, S5 and AP41 targeting portions respectively. Typically they will bind to the same receptor as the exemplary sequences provided here.

5

The S-type pyocin for use in the present invention comprises an effector portion which may have at least 80% sequence identity, e.g. at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to the effector region sequence from pyocin S2, SD2, S5 or AP41 (SEQ ID NOs: 6, 12, 17 and 23 respectively). Such effector portions may be described as S2, SD2, S5 and AP41 effector portions respectively. Typically, they have the same cytotoxic activity as the exemplary sequences provided, i.e. DNase (S2, SD2, AP41) or pore-forming (S5).

10

15

Alternatively the effector portion may be a cytotoxic domain from a colicin (e.g. a cytotoxic domain from colicin E1, E3, E9, D, Ia, E2, E7, E8, E4, E6, E5, A, B, N, M or S4. Exemplary sequences are provided in WO2014/009744) or any other suitable cytotoxic protein.

20

The pyocin molecule may have at least 80% sequence identity, e.g. at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to the exemplary sequences of pyocin S2, SD2, S5, AP41 or L1 provided above (SEQ ID NOs: 1, 7, 13, 18 and 24 respectively). Such molecules may be described as SD2, SD2, S5, AP41 or L1 pyocins respectively. Typically, they bind to the same receptors and have the same cytotoxic activity as the exemplary sequences provided. An L1 pyocin typically comprises one, two, three or four carbohydrate binding motifs which each conform to the consensus sequence shown above. In some embodiments, an L1 pyocin comprises one, two, three or all four of the specific carbohydrate binding motifs underlined in SEQ ID NO: 24 above.

25

30

35

Percent (%) amino acid sequence identity with respect to a reference sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. % identity values may be determined by WU-BLAST-2 (Altschul et al., Methods in Enzymology, 266:460-480 (1996)). WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11. A % amino acid sequence identity value is determined by the number of matching identical residues as determined by WU-BLAST-2, divided by the total number of residues of the reference sequence (gaps introduced by WU-BLAST-2 into the reference sequence to maximize the alignment score being ignored), multiplied by 100.

Pyocin proteins may be synthesised or purified by any appropriate method. For example, they may be purified from organisms (*Pseudomonas* sp.) which naturally express them, they may be synthesised by chemical methods, they may be expressed in cell-free systems, or they may be expressed by non-*Pseudomonas* host cells comprising nucleic acid encoding the relevant pyocin.

The host cell may be prokaryotic or eukaryotic, although prokaryotic hosts may be preferred since the pyocins are themselves bacterial proteins. Prokaryotic hosts may be gram-positive or gram-negative. *E. coli* is an example of a common gram-positive host cell which can readily be engineered to express pyocins by introduction of nucleic acid encoding the desired pyocin, e.g. as described in the Examples below.

Pyocins are typically encoded on plasmids. Thus, host cells may be engineered for pyocin production by introducing a plasmid encoding a pyocin, although other expression vectors or constructs may be employed, including chromosomally-integrated expression constructs.

In some cases, the host cell may be sensitive to the pyocin. In such cases it is desirable that the host cell also comprises nucleic acid encoding a complementary immunity protein (i.e. one capable of antagonising the activity of the pyocin) and is capable of expressing that immunity protein. For example, when pyocins S2, SD2 and AP41 are expressed in *E. coli*, co-expression of an immunity protein is desirable. Pyocins L1 and S5 can typically be expressed in *E. coli* in the absence of an immunity protein. The pyocin and the immunity protein may be encoded on the same expression construct (e.g. plasmid) or on different expression constructs.

Examples of immunity protein sequences include the following:

Pyocin S2 immunity protein:

MKSKISEYTEKEFLEFVKDIYTNNKKKFPTEESHIQAVLEFKKLTEHPSGSDLLYYPNENRE  
DSPAGVVKEVKEWRASKGLPGFKAG [SEQ ID NO: 25]

Pyocin SD2 immunity protein:

MSMEMIDIAKRLLASSIDGKTFSEEFFKTWRSERDSGVLAQDDASLGRCLSLMFGGLADSFTE  
GKKERPGEELTEGELKIALSDLLKEYKYI [SEQ ID NO: 26]

Pyocin S5 immunity protein:

MSFKYYWAKFFWGAFFFFVLVAWKGSVFPPLASVNPPLVVAGLSTILFPFSVKLVEDFALKYTE  
REFWVTGFFSETPAKTGLYAVFYLSCYLFSIPLGMVFLFYKYGKAS [SEQ ID NO: 27]

Pyocin AP41 immunity protein:

MDIKNNLSDYTESEFLEIIEEFFKNKSGLKGSELEKRMKLVKHFEEVTSHPRKSGVIFHPK  
PGFETPEGIVKEVKEWRAANGLPGFKAG [SEQ ID NO: 28]

The mechanism by which pyocins are released from the host cell is not well characterised. When expressed in non-*Pseudomonas* host cells, certain pyocins may be naturally secreted and thus may be recovered from the culture medium. For other pyocins, it may be convenient to recover the pyocin from the cell itself, e.g. by an appropriate lysis and purification procedure. The skilled person is well able to design suitable protocols according to their particular needs and the specific cells and proteins involved.

#### **Subjects and conditions for treatment**

The materials and methods of the present invention are suitable for prophylaxis and/or treatment of infection by *Pseudomonas*, especially *Pseudomonas aeruginosa*, and the bacterial pneumonia associated with such infection.

The infection may be acute or chronic.

*P. aeruginosa* infection of the lower respiratory tract is particularly common in patients with cystic fibrosis (where it represents the leading cause of mortality) and chronic obstructive pulmonary disease (COPD). Other patients with compromised respiratory tract function and/or compromised immune function may also be susceptible to infection, including patients with congestive heart failure, AIDS patients, and patients taking immunosuppressive medications or undergoing other immunosuppressive therapy, e.g. for cancer (especially chemotherapy) rheumatoid arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, sarcoidosis, focal segmental glomerulosclerosis, Crohn's disease, Behcet's Disease, pemphigus, ulcerative colitis, etc..

Acute conditions associated with or caused by *Pseudomonas* infection include community-acquired pneumonia and nosocomial infections such as ventilator-associated pneumonia and hospital-acquired pneumonia.

It will be appreciated that, due to variability between clinical strains of *P. aeruginosa*, not all pyocins may be effective against all strains. Factors affecting pyocin effectiveness or toxicity include differential distribution of immunity proteins amongst different strains and genetic variability in the surface receptor bound by the pyocin's targeting portion.

10 The pyocin to be administered should be effective against one or more of the infecting strains of *P. aeruginosa*. Thus it may be desirable to provide a sample of the infecting strain or strains from a subject, determine the identity of said strain or strains, and select the pyocin(s) to be administered  
15 accordingly.

For example, if the infection comprises strain P5, it may be desirable to administer a pyocin other than S2. Similarly, if the infection comprises strain E2, it may be desirable to  
20 administer a pyocin other than S2 and AP41. If the infection comprises strain P17, it may be desirable to administer a pyocin other than L1. Of course, as any infection may involve more than one strain of bacterium, it may still be desirable to include these pyocins as part of a cocktail comprising a  
25 plurality of pyocins. However, it will usually be advisable also to administer one or more pyocins having activity against the predominant species or strain(s).

Additionally or alternatively, it may be desirable to provide  
30 a sample of the infecting strain or strains from a subject, test a pyocin or a plurality of pyocins for toxicity in vitro against one or more of the infecting strains, and select one or more pyocins having appropriate toxicity for use in treating the subject.

35

The methods described above may comprise the step of obtaining the sample from the subject, or may utilise a sample already obtained.

5 Typically the subject to be treated is a mammal. The subject is typically human, but may be any other primate (great ape, old world monkey or new world monkey), or a domestic, laboratory or livestock animal, such as a mouse, rat, guinea pig, lagomorph (e.g. rabbit), cat, dog, pig, cow, horse, sheep  
10 or goat.

#### **Pharmaceutical compositions**

Delivery of pyocins for the purposes of the invention is by pulmonary administration. The term "pulmonary administration"  
15 is intended to encompass any suitable delivery method by which the active agent is delivered to the lungs via the respiratory tract.

The most common methods of pulmonary administration are oral  
20 and/or nasal inhalation. As an alternative, intra-tracheal instillation may be employed, although this is typically not considered a suitable route for clinical administration to human subjects.

25 The active agents, i.e. S-type pyocins, are typically provided in therapeutic compositions or pharmaceutically acceptable compositions. They may be formulated for pulmonary administration in any suitable manner, e.g. in a liquid or solid (typically powder) form. Formulations may be delivered  
30 by any suitable mechanism or delivery device including an inhaler (e.g. metered-dose inhaler, dry powder inhaler) nebuliser (e.g. ultrasonic nebuliser, jet nebuliser, vibrating mesh nebuliser), etc..

35 Thus the invention further provides a device for pulmonary administration of a therapeutic composition to a subject, the composition comprising an S-type pyocin as described elsewhere

in this specification. The device may be an inhaler (e.g. metered-dose inhaler, dry powder inhaler) or nebuliser (e.g. ultrasonic nebuliser, jet nebuliser, vibrating mesh nebuliser).

5

The compositions for delivery may comprise, in addition to one or more of the active agents, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the precise nature of the formulation and delivery device to be employed.

10

15

Liquid compositions generally include an aqueous carrier such as water or physiological saline solution. Dextrose or other saccharide solutions or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

20

Emulsions and nano-particle encapsulations, both employing lipids, may also be employed.

25

Solid (e.g. powder) preparations may utilise carriers such as sugars, cyclodextrins, etc. They may be prepared by any suitable method including spray drying, spray freeze drying, solvent precipitation, jet milling, etc..

30

In all cases, preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

35

Administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what

is being treated. Prescription of treatment, e.g. decisions on dosage etc., is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins.

The inventors have shown that repeated exposure to pyocins does not significantly compromise efficacy of treatment. Thus, a course of treatment may comprise or consist of a single administration or of multiple administrations. A multiple dose regime may comprise or consist of two, three, four, five, or even more individual administrations, e.g. up to ten administrations. Consecutive doses may independently be spaced by any appropriate time interval, e.g. up to 12 hours, up to one day, up to one week, up to 2 weeks, or up to one month.

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

### Examples

#### **Methods**

**Study design.** The objectives of this study were to show the efficacy of pyocins in a mouse model of acute *P. aeruginosa* lung infection and to show that pyocin treatment in the absence of infection was not harmful. For all experiments 6 week-old, female, murine pathogen free C57/BL6 mice weighing 15-21 g were used (Charles Rivers Laboratories, UK). All mice received food and water *ad libitum* and were housed in groups during the experiments. Power calculations were used to predetermine sample size (n = 6, for all treatment experiments). Mice were culled when required as determined by

a scoring system or culled at the pre-determined 24 h time point. All mice, including outliers were included in the statistical analysis. Experiments were either carried out once only or repeated once (defined for each experiment).

5

**Ethics Statement.** All animal experiments were performed in accordance with the UK Animals (Scientific procedures) Act, authorized under a UK Home Office License, and approved by the animal project review committee of the University of Glasgow.

10 Animal studies were not randomized and blinding was not possible in this study. The project license number assigned by the animal project review committee of the University of Glasgow was 60/4361.

15

**Cloning and purification of pyocins.** The genes encoding pyocin AP41 and its immunity protein (ImAP41) were amplified from the genomic DNA of *P. aeruginosa* C763 by PCR using primers designed to introduce an NdeI site at the start of the pyocin encoding gene (ACA GAT CAT ATG AGC GAC GTT TTT GAC CTT GG) and an XhoI in place of the stop codon of the ImAP41 encoding gene (ACA GAT CTC GAG GCC AGC CTT GAA GCC AGG G). The PCR product was digested with NdeI and XhoI and ligated into the corresponding sites of the *E. coli* expression vector pET21a to give pETPyoAP41, which was used for the production of the

20 pyocin AP41-ImAP41 complex in which ImAP41 carries a C-terminal His<sub>6</sub>-tag. The gene encoding pyocin S5 was similarly amplified from the genomic DNA of strain PAO1 using primers designed to introduce and NdeI site at the start of the gene (GAG ACA TAT GTC CAA TGA CAA CGA AGT AC) and an XhoI site

25 after the stop codon (TTT GAC GTC TCG AGT TAA ATG GAT ATT ACA AGA TTG TTT GC) and the digested PCR product ligated into pET15b to give pETPyoS5, which encodes pyocin S5 with an N-terminal His<sub>6</sub>-tag. Pyocins AP41 and S5 were overexpressed from

30 *E. coli* BL21 (DE3) pLysS carrying the relevant plasmid.

35

Protein production was induced by the addition of 1 mM isopropyl  $\beta$ -D-1-thiogalactopyranoside (IPTG) and the cells were grown at 37 °C for a further 4 h and harvested by

centrifugation. Cells were resuspended in 20 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole (pH 7.5) and lysed using an MSE Soniprep 150 (Wolf Laboratories) and the cell debris was separated by centrifugation. The cell-free lysate was applied to a 5-ml His Trap HP column (GE Healthcare) equilibrated in 20 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole (pH 7.5) and eluted over a 5 - 500 mM imidazole gradient. Remaining contaminants were removed by gel filtration chromatography on a Superdex S200 26/600 column (GE Healthcare). Pyocin L1 and the pyocin S2-ImS2 complex were purified as described previously <sup>(25,32)</sup>. Pyocins were concentrated using a centrifugal concentrator (Vivaspin 20) with a molecular weight cut off of 5 kDa and dialysed overnight into phosphate buffered saline, pH 7.3. Contaminating lipopolysaccharide (LPS) was removed using 1 ml gravity flow endotoxin removal columns (Thermo Scientific) and proteins were filter sterilised using a 0.2 µM syringe filter. Pyocins were aliquoted and stored at -80 °C until required.

**Pyocin sensitivity assays: overlay spot plate method.** Soft agar overlay spot plates were performed using the method of <sup>35</sup>. 150 µl of test strain culture at OD<sub>600 nm</sub> = 0.6 was added to 6 ml of 0.8% soft agar and poured over an LB agar plate. 5 µl of bacteriocin, lung homogenate or blood at varying concentrations was spotted onto the plates and incubated for 24 h at 37 °C.

**Pyocin delivery.** For pyocin delivery to the uninfected lung, 25 µl of pyocin at 3 mg ml<sup>-1</sup> (n = 4) was delivered via the intranasal route after induction of anaesthesia with isofluorane. Mice were culled at 24 h by carbon dioxide asphyxiation. A cannula was inserted into the trachea and lungs were fixed in situ by gentle infusion of 10% formalin solution at a constant pressure for 2 min. The lungs were then removed and placed in a container with more fixative. Histology processing and hematoxylin and eosin (H&E) staining was carried out by the Veterinary Diagnostic Services

Laboratory within the School of Veterinary Medicine at the University of Glasgow. High-resolution whole slide images were captured on the Leica SCN400 slide scanner and slides were scored blind by two independent assessors for peribronchial infiltrate and alveolar involvement.

**Model of acute lung infection.** Female C57/BL6 mice were inoculated intranasally with 25  $\mu$ l of bacterial culture containing approximately  $10^7$  CFU of the selected *P. aeruginosa* strain <sup>36</sup>. Antibiotic treatments were administered at either 6 h pre-infection or 1 h post-infection and were administered only once. Pyocins or tobramycin dissolved in PBS were administered via intranasal administration as described above. Two different end-points were used in these experiments. In order to determine a reduction in the bacterial load of the lungs compared to the untreated controls, all mice in the experiment were culled by carbon dioxide asphyxiation at the same time; 4-6 h post infection. To determine if mice could survive infection after pyocin or tobramycin treatment, mice were monitored closely, culled by carbon dioxide asphyxiation when required as determined by a scoring system or culled at the pre-determined 24 h time point. Uninfected mice, treated with pyocins, were used as controls in the first series of experiments in order to ensure no adverse effects from pyocin treatment. These controls were stopped in later experiments in order to reduce the number of animals used, once it was clear that the pyocins were not harmful. For CFU determination, lungs were removed aseptically and kept on ice in 750  $\mu$ l of PBS until homogenised. Serial 10-fold dilutions of the homogenised lung were plated on *Pseudomonas* selective agar (20 g peptone, 1.5 g  $K_2HPO_4$ , 1.5 g  $MgSO_4 \cdot 7H_2O$ , 10 ml glycerol, 15 g agar, 0.025 g Irgasan per litre) and incubated at 37 °C for 24 h and then room temperature for 24 h before the colonies were counted.

**Repeated pyocin exposure.** Pyocin S5 or PBS was given three times, two weeks apart with administration either via

intranasal route (referred to as I.N. groups) or intraperitoneal route (referred to as I.P. groups). For I.N. administration the groups were: PBS and pyocin S5 (75 µg; 25 µl at 3 mg ml<sup>-1</sup>). For I.P. administration the group was pyocin S5 (75 µg; 100 µl at 750 µg ml<sup>-1</sup>). The PBS I.N. group served as the control group for the I.P. group. Thirteen weeks after the first exposure mice (n = 5) were infected intranasally with *P. aeruginosa* P8 (I.N group infected with 1.4x10<sup>7</sup> CFU, I.P group infected with 5.0x10<sup>6</sup> CFU) and treated intranasally one hour post-infection with 75 µg of pyocin S5 or PBS, as described previously.

**Determination of pyocin S5-specific antibody titers by indirect ELISA.** For analysis of IgG and IgA responses, blood was obtained by cardiac puncture immediately after carbon dioxide asphyxiation. Serum was obtained by centrifugation of samples at 13,500 g for 10 min followed by collection of the supernatant. Serum was stored at -80°C. Greiner 96-well plates (MaxiSorp) were coated with purified recombinant pyocin S5 (7.5 µg ml<sup>-1</sup>, 50 µl/well) protein in PBS overnight at 4°C. The plates were washed three times with phosphate buffered saline + 0.05% TWEEN20 (PBST) and then blocked for 1 h at 37°C with 150 µl of blocking buffer (1% bovine serum albumin (BSA) in PBS). After washing, five-fold serially diluted samples were added, starting at a dilution of 1/50 in blocking buffer, and incubated for 2 h at 37°C. Serum from mice given pyocin S5 + Freund's complete/incomplete subcutaneously three times over four weeks was used as a positive control and uncoated wells were used as negative controls. Serum from individual mice were analysed and replicate samples were carried out on separate days. After washing with PBST, 50 µl of anti-mouse IgG (Fc specific)-peroxidase antibody ((1/1000 dilution) Sigma, UK) or anti-mouse IgA (α-chain specific)-peroxidase antibody ((1/250 dilution) Sigma, UK) in PBST/0.1% BSA was added and plates were incubated for 1 h at 37°C. Plates were developed using SIGMAFAST OPD (*o*-Phenylenediamine dihydrochloride) tablets (Sigma, UK) and reactions were

stopped using 3 M HCl. Optical densities (ODs) were read at 450 nm using a FLUOstar OPTIMA plate reader (BMG labtech, Germany).

5 **Statistics.** Due to small sample sizes non-parametric tests were used for analysis. The Kruskal-Wallis one-way analysis of variance method was used to test if samples originated from the same distribution. One-sided Mann-Whitney U tests with a significance threshold of  $P \leq 0.05$ , adjusted for multiple  
10 comparisons using the Bonferroni correction, was then used to analyse the specific sample pairs for significant differences. All mice, including outliers were included in the statistical analysis.

## 15 **Results**

### **Pyocins are stable in the murine lung and do not cause inflammation or tissue damage**

To determine if pyocins can be effectively delivered to the lungs and if they are stable in this environment, recombinant  
20 pyocins S2, S5, AP41 and L1 were administered intranasally to healthy C57/BL6 mice. After a 24 h incubation period, the postcaval lobe was removed from treated mice, homogenized and tested for the presence of active pyocin by spotting onto a growing lawn of *P. aeruginosa* (strain P8 for most pyocins and  
25 P17 for pyocin S2) . Killing of *P. aeruginosa* was detected with lung homogenates from pyocin L1, S2 and S5 treated mice, but was not observed in homogenates from pyocin AP41 or PBS treated mice (data not shown). These data indicate that  
30 pyocins are well distributed through the lung after intranasal administration and in the case of pyocins L1, S2 and S5 are stable in this environment. For pyocin AP41, activity was not detected. This could be due to the sensitivity of the *P. aeruginosa* indicator strain or could indicate that this pyocin may be more rapidly degraded than the other tested pyocins *in vivo*. To ascertain if pyocins could be harmful to the host,  
35 pyocins were again administered intranasally and after 24 h pyocin treated lungs were fixed. Lung tissues visualised using

hematoxylin and eosin staining were then scored for peribronchial infiltrate and alveolar macrophage involvement. The pyocin treated lungs showed no signs of such features, and were indistinguishable from the PBS treated tissue, indicating that the administration of a single high-concentration dose of any of this diverse group of protein antibiotics does not lead to overt inflammation or tissue damage (data not shown).

#### **Pyocins can afford protection against lethal *P. aeruginosa* infections**

To determine if pyocins are sufficiently active to reduce bacterial load in the lung, pyocins S2, S5, AP41 and L1 (3 mg ml<sup>-1</sup>), or PBS for control mice, were administered intranasally 6 h pre-infection with a normally lethal dose of *P. aeruginosa* P8 (approx 10<sup>7</sup> CFU). All mice were culled 4 h post-infection and viable bacterial counts from lung homogenates determined (Figure 1a). All pyocins reduced bacterial load, although at this time point differences in efficacy were noted, with pyocins S2, AP41 and L1 reducing bacterial numbers by approximately 25-fold, 650-fold and 1500-fold, respectively. In the case of pyocin S5, no viable bacteria were recovered.

In order to determine if pyocin activity is sufficient to afford protection against a normally lethal dose of *P. aeruginosa*, mice were similarly pre-treated with pyocins 6 h pre-infection with *P. aeruginosa* P8, monitored for sickness and culled on reaching a pre-determined severity of illness clinical score. Five out of six of the PBS control mice were culled at 5 h post-infection whereas all pyocin treated mice survived to the endpoint of the experiment at 24 h. Viable bacterial counts at this time point indicated a similar killing activity for pyocins S2, AP41 and L1, which all significantly reduced bacterial counts more than 10,000-fold. Again, at this time point no viable bacteria were recovered from pyocin S5 treated mice (Figure 1b).

A similar experiment was performed using pyocin SD2. C57/BL6 mice (n=6) were infected with approx  $1.5 \times 10^7$  CFU of *P. aeruginosa* PA01 and treated 1 h post-infection with pyocin SD2 at  $3 \text{ mg ml}^{-1}$ . Infected mice were monitored for sickness and  
5 culled if a sufficient clinical score was reached, or alternatively at the endpoint of the experiment, 24 h post-infection. Pyocin SD2 treated mice survived to the endpoint of the experiment at 24 h, control mice were culled 6 h post infection. The bacterial load of the lungs was determined and  
10 control mice had approx  $2 \times 10^5$  CFU/lung, 6 h after infection. For pyocin SD2 mice, either no colonies or 10 CFU/lung were recovered 24 h post-infection (Figure 7).

The ability of pyocins to reduce bacterial numbers on  
15 administration post-infection was then determined. *P. aeruginosa* P8 infected mice were treated 1 h post-infection with pyocins S2, S5, AP41 and L1 at  $3 \text{ mg ml}^{-1}$ . In these experiments mice were culled at 4.5 h post-infection and bacterial counts from lung homogenates were compared to PBS  
20 treated controls. Similar to the pre-treatment experiments, pyocin S5 showed greatest efficacy in reducing bacterial numbers, although in this experiment viable bacteria were recovered from three out of six S5 treated mice. Pyocins L1, S2, and AP41 significantly reduced the bacterial load by  
25 approximately 20-, 80- and 130-fold, respectively (Figure 1c). This experiment was repeated and again all pyocin treated groups showed significantly reduced bacterial counts (Figure 5a).

To determine if pyocin treatment post-infection affords  
30 protection against lethal *P. aeruginosa* infection, mice were similarly infected with *P. aeruginosa* P8 and treated 1 h post-infection with pyocins S2, S5, AP41 and pyocin L1 at  $3 \text{ mg ml}^{-1}$ . Infected mice were monitored for sickness and culled if  
35 sufficient clinical score were reached, or alternatively at the endpoint of the experiment, 24 h post-infection. All PBS treated mice were culled at 4.5 h post-infection and all

pyocin treated mice survived to the endpoint of the experiment at 24 h. The bacterial load of the lungs was determined and again pyocin S5 showed the greatest efficacy with no bacteria recovered from any of the six pyocin S5 treated mice. In addition, pyocins S2, L1 and AP41 were also highly effective in this model significantly reducing bacterial counts in excess of 4-log units (Figure 1d). This experiment was repeated and again all pyocin treated mice survived to 24 h and bacterial counts were similarly significantly reduced (Figure 5b). Thus, pyocins are highly effective in reducing bacterial load in the lung and are able to afford protection against a lethal *P. aeruginosa* infection when administered pre- and post-infection.

Since strains of *P. aeruginosa* are phenotypically diverse, we tested the efficacy of the pyocins against three additional isolates: *P. aeruginosa* P17 and *P. aeruginosa* P5 (mucoid), both from cystic fibrosis patients and *P. aeruginosa* E2, an environmental isolate. Pyocin S2 was not active against *P. aeruginosa* P5 or *P. aeruginosa* E2 *in vitro* therefore was not used to treat these strains *in vivo* and similarly pyocin L1 was not used against *P. aeruginosa* P17. All three *P. aeruginosa* strains showed levels of virulence similar to that of *P. aeruginosa* P8 in the model of acute lung infection and *P. aeruginosa* P5, P17 and E2 infected controls all required culling at 4.5 h, 4 h and 5.5 h post-infection, respectively. Pyocin S5, L1 and S2 treated mice infected with *P. aeruginosa* P17, P5 or E2 all survived until the 24 h endpoint of the experiment and viable bacterial counts were either reduced to significantly low levels or absent (Table 1). In contrast, treatment of *P. aeruginosa* E2 with pyocin AP41 failed to afford protection and these mice were culled at 5.5 h post-infection. Lung homogenates from *P. aeruginosa* E2-infected AP41-treated mice contained high levels of viable bacteria, reduced only 10-fold relative to control mice (Table 1). Pyocin AP41 treatment, however, was successful for *P. aeruginosa* P5 infected mice and for five out of six of the *P.*

*aeruginosa* P17 infected mice. Thus, pyocins show strong efficacy against diverse strains of *P. aeruginosa* with pyocin S5 treatment displaying the largest effect on reducing bacterial load.

Treatment	P5	P17	E2
No treatment	1.7x10 <sup>5</sup> CFU/lung	4.4x10 <sup>5</sup> CFU/lung	1.5x10 <sup>5</sup> CFU/lung
Pyocin L1	40	X	No colonies detected
Pyocin S2	X	No colonies detected	X
Pyocin AP41	No colonies detected	No colonies detected +	1.3x10 <sup>4</sup> CFU/lung *
Pyocin S5	No colonies detected	No colonies detected	No colonies detected

**Table 1.** Pyocin treatment for a range of *P. aeruginosa* isolates. Mice were infected with a lethal dose of *P. aeruginosa*. Untreated mice were culled 4 h-5.5 h post infection. Pyocin treated mice (3 mg ml<sup>-1</sup>) survived to 24 h. \*Mice culled at same time as control. +1 mouse coughed up AP41 treatment and was culled at 4 h post-infection, bacterial count 1.3x10<sup>5</sup> CFU/lung. X - Pyocin was not used against this strain.

**Pyocin S5 shows improved killing of *P. aeruginosa* in the murine lung compared to tobramycin**

To compare pyocin efficacy directly with a current frontline treatment, we compared pyocin S5 with tobramycin, which is widely used as an inhaled treatment for *P. aeruginosa* lung infection in patients with cystic fibrosis. Mice were infected as before with *P. aeruginosa* P8 and treated 1 h post-infection with either tobramycin at 30 or 3 mg ml<sup>-1</sup> or pyocin S5 at 0.3 or 3 mg ml<sup>-1</sup>, culled 4.5 h post-infection and viable bacterial counts determined from lung homogenates. All four treatments significantly reduced the bacterial load compared to the PBS controls. Pyocin S5 at both concentrations reduced the bacterial load to a greater extent than tobramycin (Figure 2a). This experiment was repeated and again pyocin S5 reduced bacterial counts to a greater extent than tobramycin (Figure 6). To determine the relative potency of pyocin S5 compared to tobramycin, *P. aeruginosa* P8 infected mice were treated with pyocin S5 at 30 ng ml<sup>-1</sup>, 300 pg ml<sup>-1</sup> or 3 pg ml<sup>-1</sup> and tobramycin

at 300  $\mu\text{g ml}^{-1}$ , 3  $\mu\text{g ml}^{-1}$  or 30  $\text{ng ml}^{-1}$ . Groups treated with pyocin S5 at 30  $\text{ng ml}^{-1}$  and tobramycin at 300  $\mu\text{g ml}^{-1}$  survived to 24 h, all other groups were culled 5.5 h post-infection due to the severity of the infection. 24 h post-infection both pyocin S5 at 30  $\text{ng ml}^{-1}$  and tobramycin at 300  $\mu\text{g ml}^{-1}$  had significantly reduced the bacterial counts compared to the PBS controls (Figure 2b). These results show that the lowest concentration at which pyocin S5 is effective lies between 30  $\text{ng ml}^{-1}$  and 300  $\text{pg ml}^{-1}$  and the lowest concentration at which tobramycin is effective lies between 300  $\mu\text{g ml}^{-1}$  and 3  $\mu\text{g ml}^{-1}$ . Pyocin S5 is therefore at least 100-fold more potent than tobramycin in this model of infection (Table 2).

Pyocin	Lowest active concentration tested	Corresponding molarity
Pyocin L1	30 $\mu\text{g ml}^{-1}$	1.06 $\mu\text{M}$
Pyocin S2	30 $\mu\text{g ml}^{-1}$	358 nM
Pyocin AP41	30 $\mu\text{g ml}^{-1}$	319 nM
Pyocin S5	30 $\text{ng ml}^{-1}$	535 pM
Tobramycin	300 $\mu\text{g ml}^{-1}$	641 $\mu\text{M}$

**Table 2.** Minimum concentration of pyocin tested that affords protection against *P. aeruginosa* P8 infection. The lowest active concentration tested represents the lowest concentration tested with which the treated mice survived to 24 h.

After ascertaining that pyocin S5 is effective in this model at a concentration lower than 1 nM, we tested the efficacy of pyocins S2, L1 and AP41 at lower concentrations than previously used. All three pyocins were used at 300  $\mu\text{g ml}^{-1}$  and 30  $\mu\text{g ml}^{-1}$ . Due to the severity of symptoms three of the six mice treated with pyocin L1 at 30  $\mu\text{g ml}^{-1}$  and PBS control mice were culled at 6 h post-infection. All mice treated with pyocins S2 and AP41 at both concentrations and mice treated with pyocin L1 at 300  $\mu\text{g ml}^{-1}$  survived until the endpoint of the experiment at 24 h post-infection (Table S1). Thus against *P. aeruginosa* P8, the minimum effective concentration of pyocins S2 and AP41 is  $\leq 30 \mu\text{g ml}^{-1}$  and the minimum effective

concentration of pyocin L1 is between 30 and 300  $\mu\text{g ml}^{-1}$ . Table S1 shows that all pyocins tested *in vivo* displayed a potency that was comparable to or greater than tobramycin.

#### 5 **Pyocin tolerance and mitigation strategies**

In order to determine if pyocin tolerance or resistance was acquired upon pyocin treatment *in vivo*, viable bacteria recovered from mice that survived infection to the 24 h end-point, in all experiments discussed in this work, were tested  
10 for pyocin susceptibility. From these experiments no pyocin resistant colonies were isolated. However, we obtained a single isolate (P8AP41T) from pyocin AP41 (3  $\text{mg ml}^{-1}$  post-infection) treated bacteria that showed increased tolerance (approximately 1000-fold) to pyocin AP41. Importantly,  
15 sensitivity to pyocins S5 and L1 were unaffected *in vitro* in this pyocin AP41-tolerant strain (Figure 3a) and this was also shown to be the case *in vivo* when mice were infected with P8AP41T. In contrast to PBS controls, which were culled 6 h post-infection, pyocin treated (3  $\text{mg ml}^{-1}$ ) P8AP41T infected mice  
20 survived until the endpoint of the experiment at 24 h and had significantly reduced bacterial numbers in lung homogenates (Figure 3b). Interestingly, this applied not only to treatment with pyocins L1, S2, S5, but also to treatment with pyocin AP41, indicating that this pyocin AP41-tolerant mutant can  
25 still be successfully treated with pyocin AP41 at high concentrations. Pyocin susceptibility testing showed that this strain remained tolerant to pyocin AP41 during infection (Figure 3a).

30 As all four pyocins used in this study parasitise different nutrient uptake receptors in *P. aeruginosa* an obvious strategy to prevent the occurrence of pyocin resistance is to use 'pyocin cocktails' consisting of two or more pyocins in combination. We therefore tested the efficacy of combinations  
35 of two or more pyocins in the acute lung infection model with *P. aeruginosa* P8. The following pyocin combinations were tested: L1/S2, L1/AP41, S2/AP41 and L1/S2/AP41 with all

pyocins at 300  $\mu\text{g ml}^{-1}$ . PBS control mice were culled 4.5 h post-infection and all pyocin treated mice survived until 24 h. Viable bacteria were recovered at a low level from pyocin treated mice and for the combination of L1/S2/AP41, bacteria were recovered from only one of six treated mice, indicating that pyocin combinations show enhanced efficacy over the use of individual pyocins (Figure 4). No pyocin resistance or tolerance was observed for bacteria recovered after treatment with multiple pyocins.

#### **Pyocin S5 can afford protection against lethal *P. aeruginosa* infections in the presence of pyocin S5 antibodies**

To ascertain if repeated exposure to pyocins gives rise to an antibody response that is detrimental to treatment, mice were repeatedly exposed to pyocin S5 to induce an antibody response and the efficacy of pyocin treatment was determined as before after infection with *P. aeruginosa* P8. Pyocin S5 was administered three times, with two weeks between each administration, either via the intranasal route (I.N.) or the intraperitoneal (I.P.) route. Thirteen weeks after the first treatment, mice ( $n = 5$ ) were infected intranasally with *P. aeruginosa* P8 (I.N. group infected with  $1.4 \times 10^7$  CFU, I.P. group infected with  $5.0 \times 10^6$  CFU) and treated intranasally 1 h post-infection with 75  $\mu\text{g}$  of pyocin S5 or PBS. A control group administered only PBS intranasally prior to infection was also included. For the I.N. groups, all pyocin S5 treated mice survived to the 24 h time-point, while all PBS-treated mice were culled 5 h post-infection due to severity of symptoms. The bacterial load of the lungs was determined and no viable bacteria were recovered from any of the pyocin S5 treated mice (Figure 8a). The levels of pyocin-S5 specific IgG and IgA were analysed for each mouse. There were no IgA antibodies detected in these mice; however there were low levels of IgG present in the mice previously exposed to pyocin S5 (10-fold less than the Freund's complete/incomplete control group) (Figure 8b). For the mice repeatedly exposed to pyocin S5 via the I.P. route, mice treated with pyocin S5 intranasally post-infection

all survived to the 24 h time-point and PBS-treated mice were  
culled 5 h post-infection due to the severity of symptoms. The  
bacterial load of the lungs was determined and no viable  
bacteria were recovered from any of the pyocin S5 treated mice  
5 (Figure 8c). The pyocin S5-specific IgG levels were very low  
in the pyocin S5 only group (1000-fold less than the Freund's  
complete/incomplete control group) and no pyocin S5-specific  
IgA was detected (Figure 8d). Thus, pyocin S5 shows strong  
efficacy after repeated administration and in the presence of  
10 pyocin-S5 specific antibodies.

### Discussion

In this work we have shown that pyocins are highly effective  
in reducing bacterial load and affording protection in a  
15 lethal model of acute *P. aeruginosa* lung infection when  
delivered directly to the lung. Notably, pyocin S5 was shown  
to afford protection at a concentration that is at least 100-  
fold lower than the minimum effective concentration of  
tobramycin, an antibiotic that is widely used to treat *P.*  
20 *aeruginosa* lung infections. All pyocins tested *in vivo*  
displayed a potency that was comparable to or greater than  
tobramycin. In addition, the administration of these highly  
stable, chromosomally encoded pyocins at high concentrations  
did not lead to overt inflammation or tissue damage in the  
25 lung. Taken together, these data suggest that pyocins have the  
potential to make useful therapeutics for the treatment of *P.*  
*aeruginosa* lung infections. These include *P. aeruginosa*  
infections associated with cystic fibrosis, hospital-acquired  
and ventilator-associated pneumonia and chronic obstructive  
30 pulmonary disease (COPD), all of which are areas of current  
unmet medical need<sup>10,11</sup>. Indeed, related colicin-like and  
lectin-like bacteriocins may also make useful therapeutics for  
the treatment of respiratory infections with frequently  
antibiotic-resistant pathogens such as *Klebsiella pneumoniae*  
35 and *Burkholderia* spp.

In addition to their potency, an additional advantage of the colicin-like bacteriocins is their narrow spectrum of killing. This allows for the possibility of successfully treating bacterial infections while leaving the normal bacterial flora intact. Well-established complications associated with the use of broad-spectrum antibiotics and dysbiosis include antibiotic-associated diarrhea and *Clostridium difficile* infection<sup>26,27</sup>. More recently, microbial imbalances have been suggested to play a role in a range of chronic diseases such as Crohn's disease, diabetes, obesity and rheumatoid arthritis<sup>28-31</sup>.

Of the pyocins tested in this study, the receptors for pyocins S2 and S5 are known to be the TonB-dependent iron-siderophore receptors FpvAI and FptA, respectively<sup>21,22</sup> and the receptor for pyocin L1 has recently been shown to be the common polysaccharide antigen (CPA) of lipopolysaccharide<sup>32</sup>. However, the receptor for pyocin AP41 remains to be discovered. FptA and the CPA are known to be widely distributed among strains of *P. aeruginosa*<sup>33</sup> and interestingly CPA production by *P. aeruginosa* has been shown to be up-regulated in the cystic fibrosis lung<sup>34</sup>, meaning that pyocin L1 may be active against strains *in vivo* for which no *in vitro* activity can be detected. Using a 'cocktail' of pyocins that target different cell surface receptors will reduce the chances of acquired pyocin resistance and also reduce the probability of resistance imparted by the presence of a pyocin-specific immunity protein genes in pyocin-producing strains. However, inherent pyocin-specific immunity is not a great limitation of these antimicrobials as pyocins AP41 and S5 are active against 87% of strains in a collection of diverse environmental and clinical isolates.

\*\*\*

While the invention has been described in conjunction with the exemplary embodiments described above, many equivalent modifications and variations will be apparent to those skilled

in the art when given this disclosure. Accordingly, the exemplary embodiments of the invention set forth are considered to be illustrative and not limiting. Various changes to the described embodiments may be made without departing from the spirit and scope of the invention. All documents cited herein are expressly incorporated by reference.

**References**

- 1 Souli, M., Galani, I., & Giamarellou, H., (2008)  
Emergence of extensively drug-resistant and pandrug-resistant  
Gram-negative bacilli in Europe. *Eurosurveillance*. **13**, 19045-  
5 19045.
- 2 Vila, J. & Luis Martinez, J., Clinical Impact of the  
Over-Expression of Efflux Pump in Nonfermentative Gram-  
Negative Bacilli, Development of Efflux Pump Inhibitors.  
(2008) *Current Drug Targets*. **9**, 797-807.
- 10 3 Nikaido, H., Molecular basis of bacterial outer membrane  
permeability revisited. (2003) *Microbiol Mol Biol Rev*. **67**,  
593-656.
- 4 Flamm, R.K. et al., Factors associated with relative  
rates of antibiotic resistance in *Pseudomonas aeruginosa*  
15 isolates tested in clinical laboratories in the United States  
from 1999 to 2002. (2004) *Antimicrob Agents Chemother*. **48**,  
2431-2436.
- 5 Mah, T.F. et al., A genetic basis for *Pseudomonas*  
*aeruginosa* biofilm antibiotic resistance. (2003) *Nature*. **426**,  
20 306-310.
- 6 Drenkard, E. & Ausubel, F.M., *Pseudomonas* biofilm  
formation and antibiotic resistance are linked to phenotypic  
variation. (2002) *Nature*. **416**, 740-743.
- 7 Livermore, D.M., Multiple mechanisms of antimicrobial  
25 resistance in *Pseudomonas aeruginosa*: Our worst nightmare?  
(2002) *Clinical Infectious Diseases*. **34**, 634-640.
- 8 Cystic Fibrosis Trust Annual data report 2011, UK CF  
Registry, 2013.
- 9 Chastre, J. & Fagon, J.Y., Ventilator-associated  
30 pneumonia. (2002) *American Journal of Respiratory and Critical*  
*Care Medicine*. **165**, 867-903.
- 10 Planquette, B. et al., *Pseudomonas aeruginosa* Ventilator-  
associated Pneumonia Predictive Factors of Treatment Failure.

(2013) *American Journal of Respiratory and Critical Care Medicine*. **188**, 69-76.

- 11 Martinez-Solano, L., Macia, M.D., Fajardo, A., Oliver, A., & Martinez, J.L., Chronic *Pseudomonas aeruginosa* Infection  
5 in Chronic Obstructive Pulmonary Disease. (2008) *Clinical Infectious Diseases*. **47**, 1526-1533.
- 12 Murphy, T.F. et al., *Pseudomonas aeruginosa* in chronic obstructive pulmonary disease. (2008) *American Journal of Respiratory and Critical Care Medicine*. **177**, 853-860.
- 10 13 Payne, D.J., Gwynn, M.N., Holmes, D.J., & Pompliano, D.L., Drugs for bad bugs: confronting the challenges of antibacterial discovery. (2007) *Nat Rev Drug Discov*. **6**, 29-40.
- 14 Bumann, D., Has nature already identified all useful  
15 antibacterial targets? (2008) *Current Opinion in Microbiology*. **11**, 387-392.
- 15 Shlaes, D.M., Sahm, D., Opiela, C., & Spellberg, B., The FDA Reboot of Antibiotic Development. (2013) *Antimicrob Agents Chemother*. **57**, 4605-4607.
- 20 16 Michel-Briand, Y. & Baysse, C., The pyocins of *Pseudomonas aeruginosa*. (2002) *Biochimie*. **84**, 499-510.
- 17 Cascales, E. et al., Colicin biology. (2007) *Microbiol Mol Biol Rev*. **71**, 158-229.
- 18 Parret, A.H.A. & De Mot, R., Bacteria killing their own  
25 kind: novel bacteriocins of *pseudomonas* and other gamma-proteobacteria. (2002) *Trends Microbiol*. **10**, 107-112.
- 19 Ferguson, A.D. & Deisenhofer, J., TonB-dependent receptors - structural perspectives. (2002) *Biochimica Et Biophysica Acta-Biomembranes*. **1565**, 318-332.
- 30 20 Kleanthous, C., Swimming against the tide: progress and challenges in our understanding of colicin translocation. (2010) *Nat. Rev. Microbiol*. **8**, 843-848.

- 21 Elfarash, A., Wei, Q., & Cornelis, P., The soluble pyocins S2 and S4 from *Pseudomonas aeruginosa* bind to the same FpvAI receptor. (2012) *MicrobiologyOpen*. **1**, 268-275.
- 22 Elfarash, A. et al., Pore-forming pyocin S5 utilizes the  
5 FptA ferripyochelin receptor to kill *Pseudomonas aeruginosa*. (2014) *Microbiology*. **160**, 261-269.
- 23 Housden, N.G. et al., Intrinsically Disordered Protein Threads Through the Bacterial Outer-Membrane Porin OmpF. (2013) *Science*. **340**, 1570-1574.
- 10 24 Baysse, C. et al., Uptake of pyocin S3 occurs through the outer membrane ferripyoverdine type II receptor of *Pseudomonas aeruginosa*. (1999) *J Bacteriol*. **181**, 3849-3851.
- 25 Smith, K. et al., Activity of Pyocin S2 against  
15 *Pseudomonas aeruginosa* Biofilms. (2012) *Antimicrob Agents Chemother*. **56**, 1599-1601.
- 26 Gorkiewicz, G., Nosocomial and antibiotic-associated diarrhoea caused by organisms other than *Clostridium difficile*. (2009) *Int J Antimicrob Agents*. **33**, S37-S41.
- 27 Carroll, K.C. & Bartlett, J.G., Biology of *Clostridium*  
20 *difficile*: Implications for Epidemiology and Diagnosis. (2011) *Annu Rev Microbiol*. **65**, 501-521.
- 28 Manichanh, C., Borrueal, N., Casellas, F., & Guarner, F., The gut microbiota in IBD. (2012) *Nat Rev Gastroenterol Hepatol*. **9**, 599-608.
- 25 29 Qin, J. et al., A metagenome-wide association study of gut microbiota in type 2 diabetes. (2012) *Nature*. **490**, 55-60.
- 30 Scher, J.U. & Abramson, S.B., The microbiome and rheumatoid arthritis. (2011) *Nat Rev Rheumatol*. **7**, 569-578.
- 31 Henao-Mejia, J. et al., Inflammasome-mediated dysbiosis  
30 regulates progression of NAFLD and obesity. (2012) *Nature*. **482**, 179-U167.
- 32 McCaughey, L.C. et al., Lectin-like bacteriocins from *Pseudomonas* spp. utilise D-rhamnose containing

lipopolysaccharide as a cellular receptor. (2014) *PLoS Pathog.* **10**, e1003898.

33 Hao, Y., King, J.D., Huszczyński, S., Kocincova, D., & Lam, J.S., Five New Genes Are Important for Common  
5 Polysaccharide Antigen Biosynthesis in *Pseudomonas aeruginosa*.  
(2013) *Mbio.* **4**.

34 Weisner, A.M., Chart, H., Bush, A., Davies, J.C., & Pitt, T.L., Detection of antibodies to *Pseudomonas aeruginosa* in  
10 serum and oral fluid from patients with cystic fibrosis.  
(2007) *J Med Microbiol.* **56**, 670-674.

35 Fyfe, J.A.M., Harris, G., & Govan, J.R.W., Revised Pyocin  
Typing Method For *Pseudomonas-Aeruginosa*. (1984) *J Clin  
Microbiol.* **20**, 47-50.

36 Bragonzi, A., Murine models of acute and chronic lung  
15 infection with cystic fibrosis pathogens. (2010) *International  
Journal of Medical Microbiology.* **300**, 584-593.

37 Kageyama M, Kobayashi M, Sano Y, Masaki H. (1996)  
Construction and characterization of pyocin-colicin chimeric  
20 proteins. *J Bacteriol.* **178(1)**, 103-10.

**Claims**

- 5 1. An S-type pyocin for use in a method of prophylaxis or treatment of a bacterial respiratory infection, wherein the pyocin is delivered by pulmonary administration.
- 10 2. A method for prophylaxis or treatment of bacterial respiratory infection in a subject wherein an S-type pyocin is delivered to the subject by pulmonary administration.
- 15 3. An S-type pyocin for use according to claim 1 or method according to claim 2 wherein the infecting bacteria comprise *Pseudomonas aeruginosa*.
- 20 4. An S-type pyocin or method according to any one of claims 1 to 3 wherein the subject to be treated has, or is at risk of developing, a bacterial pneumonia.
- 25 5. An S-type pyocin or method according to claim 4 wherein the subject to be treated has compromised respiratory tract function and/or compromised immune function.
- 30 6. An S-type pyocin or method according to claim 4 or claim 5 wherein the subject to be treated is suffering from cystic fibrosis or chronic obstructive pulmonary disease.
- 35 7. An S-type pyocin or method according to claim 4 or claim 5 wherein the subject is a cancer patient or a patient affected by congestive heart failure or AIDS.
8. An S-type pyocin or method according to any one of claims 4 to 7 wherein the subject to be treated has, or is at risk of developing, community-acquired pneumonia, ventilator-associated pneumonia or hospital-acquired pneumonia.
9. An S-type pyocin or method according to any one of the preceding claims wherein the S-type pyocin comprises an S2, SD2, S5 or AP41 targeting portion.

10. An S-type pyocin or method according to claim 9 wherein the pyocin comprises an S5 targeting portion.

5 11. An S-type pyocin or method according to any one of the preceding claims wherein the S-type pyocin comprises an S2, SD2, S5 or AP41 effector portion.

10 12. An S-type pyocin or method according to claim 11 wherein the S-type pyocin comprises an S5 effector portion.

13. An S-type pyocin or method according to any one of the preceding claims wherein the S-type pyocin is an SD2, S2, S5, AP41 or L1 pyocin.

15 14. An S-type pyocin or method according to claim 13 wherein the S-type pyocin is an S5 pyocin.

20 15. An S-type pyocin or method according to any one of the preceding claims wherein a combination of two or more pyocins is administered to the subject.


25 16. An S-type pyocin or method according to claim 15 wherein the combination comprises an S5 pyocin, an L1 pyocin, an S2 pyocin, an SD2 pyocin and/or an AP41 pyocin.

30 17. An S-type pyocin or method according to claim 16 wherein the combination comprises an L1 pyocin and an S2 pyocin; an L1 pyocin and an AP41 pyocin; an S2 pyocin and an AP41 pyocin; or an L1 pyocin, an S2 pyocin and an AP41 pyocin; optionally in combination with an S5 pyocin and/or an SD2 pyocin.


35 18. A method of preparing a medicament for the prophylaxis or treatment of a bacterial respiratory infection comprising providing an S-type pyocin and formulating said S-type pyocin for pulmonary administration.

19. A device for pulmonary administration of a therapeutic composition to a subject, wherein the composition comprises an S-type pyocin.


5 20. A device according to claim 19 which is an inhaler or nebuliser.




**FIG. 1**




**FIG. 2**




**FIG. 3**




**FIG. 4**




**FIG. 5**



**FIG. 6**



**FIG. 7**



**FIG. 8**

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2015/071768

## Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
  - a.  forming part of the international application as filed:
    - in the form of an Annex C/ST.25 text file.
    - on paper or in the form of an image file.
  - b.  furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
  - c.  furnished subsequent to the international filing date for the purposes of international search only:
    - in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
    - on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.  In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

# INTERNATIONAL SEARCH REPORT

International application No PCT/EP2015/071768
---

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> INV. A61K38/16      A61K9/00      C07K14/21      A61P31/04 ADD.				
According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b>				
Minimum documentation searched (classification system followed by classification symbols) A61K C07K A61P				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, BIOSIS, EMBASE, WPI Data				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	US 2008/286236 A1 (GEBHART DANA M [US] ET AL) 20 November 2008 (2008-11-20) see claims 1-11, [034]-[035], [048], [053], [071]-[073], [096] -----	1,2,4-17		
Y	SCHOLL DEAN ET AL: "Antibacterial efficacy of R-type pyocins towards Pseudomonas aeruginosa in a murine peritonitis model", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 52, no. 5, May 2008 (2008-05), pages 1647-1652, XP002751100, ISSN: 0066-4804 see abstract, page 1648 and page 1651 last paragraph ----- -/--	1,2,4-17		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
* Special categories of cited documents : <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;">                     "A" document defining the general state of the art which is not considered to be of particular relevance                      "E" earlier application or patent but published on or after the international filing date                      "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)                      "O" document referring to an oral disclosure, use, exhibition or other means                      "P" document published prior to the international filing date but later than the priority date claimed                 </td> <td style="width: 50%; border: none; vertical-align: top;">                     "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention                      "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone                      "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art                      "&amp;" document member of the same patent family                 </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search	Date of mailing of the international search report			
19 November 2015	12/01/2016			
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Merckling-Ruiz, V			

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2015/071768

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CARLA L. BROWN ET AL: "Colicin-like bacteriocins as novel therapeutic agents for the treatment of chronic biofilm-mediated infection", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 7, no. 6, 21 November 2012 (2012-11-21), pages 521-1552, XP055079887, ISSN: 0300-5127, DOI: 10.3748/wjg.v17.i14.1797	18
Y	the whole document	1,2,4-17
Y	----- DE KWAADSTENIET M ET AL: "Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus", LETTERS IN APPLIED MICROBIOLOGY, vol. 48, no. 1, January 2009 (2009-01), pages 65-70, XP002751101, ISSN: 0266-8254 see abstract and page 66	1,2,4-17
X	----- ELFARASH A ET AL: "Pore-forming pyocin S5 utilizes the FptA ferripyochelin receptor to kill Pseudomonas aeruginosa", MICROBIOLOGY (UNITED KINGDOM) FEB 2014 SOCIETY FOR GENERAL MICROBIOLOGY GBR, vol. 160, no. PART 2, February 2014 (2014-02), pages 261-269, XP002751102, ISSN: 1350-0872	18
Y	see abstract and page 267	1,2,4-17
Y	----- HUA LING ET AL: "A predicted S-type pyocin shows a bactericidal activity against clinical isolates through membrane damage", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 584, no. 15, 14 June 2010 (2010-06-14), pages 3354-3358, XP028340497, ISSN: 0014-5793, DOI: 10.1016/J.FEBSLET.2010.06.021 [retrieved on 2010-06-18] see abstract and page 3356-3357	1,2,4-17
	-----	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No  
PCT/EP2015/071768

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2008286236	A1	NONE	
-----			